Natural Killer Cells Therapeutics Market by Therapeutics, Application and End User - Global Industry Analysis & Forecast to 2027
Published On : July 2019 Pages : 146 Category: Pharmaceuticals Report Code : HC084543
Natural Killer Cells Therapeutics Market by Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Application (Cancer, Immunoproliferative Disorders, Gastrointestinal Diseases, and Others), and End User (Hospitals, Research Centers & Institutes, and Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Natural killer cells are enormous granular lymphocytes that react rapidly to an obsessive test. Moreover, they are in charge of delivering immunoregulatory cytokines. Also, they go about as a significant segment of the natural invulnerable arrangement of a human. The key job of NK cells is to produce an invulnerable reaction against malignancies and viral contaminations.
Drivers and Restraints
Ascend in selection of NK cells for the treatment of malignancy, contaminations, and liver illnesses is a key factor that drives the development of the natural killer cells therapeutics market. Likewise, NK cells assume a critical job in tumor insusceptible reconnaissance, which lifts the appropriation of NK therapeutics over the globe. Also, ascend in mindfulness among the populace with respect to different immunotherapies and increment in R&D for the advancement of bi-explicit counter acting agent for drawing in NK cells to dispose of tumor cells drive the worldwide market development. Nonetheless, absence of explicitness and poor in-vivo survival of as far as possible the natural killer cells therapeutics market development.
Regional Insights
The North America natural killer cells therapeutics market of the overall industry represented the most elevated offer in 2018 and is required to proceed with its strength all through the estimate time frame.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Affimed N.V.
- Fate Therapeutics
- Glycostem Therapeutics BV
- Nantkwest Inc.
- NKT Therapeutics Inc.
- Celgene Corporation
- Fortress Biotech
- Innate Pharma S.A.
- Nkarta Therapeutics, Inc.
- Ziopharm Oncology Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Natural Killer Cells Therapeutics Market, By Therapeutics, Estimates and Forecast, 2017-2027 ($Million)
o NK Cell Therapies
o NK Cell Directed Antibodies
· Natural Killer Cells Therapeutics Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Cancer
o Immunoproliferative Disorders
o Gastrointestinal Diseases
o Others
· Natural Killer Cells Therapeutics Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals
o Research Centers & Institutes
o Others
· Natural Killer Cells Therapeutics Market, By Key Players
o Affimed N.V.
o Fate Therapeutics
o Glycostem Therapeutics BV
o Nantkwest Inc.
o NKT Therapeutics Inc.
o Celgene Corporation
o Fortress Biotech
o Innate Pharma S.A.
o Nkarta Therapeutics, Inc.
o Ziopharm Oncology Inc.
· Natural Killer Cells Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Natural Killer Cells Therapeutics Market, By Country
o U.S. Natural Killer Cells Therapeutics Market
o Canada Natural Killer Cells Therapeutics Market
o Mexico Natural Killer Cells Therapeutics Market
o Europe
§ Europe Natural Killer Cells Therapeutics Market, By Country
o Germany Natural Killer Cells Therapeutics Market
o UK Natural Killer Cells Therapeutics Market
o France Natural Killer Cells Therapeutics Market
o Russia Natural Killer Cells Therapeutics Market
o Italy Natural Killer Cells Therapeutics Market
o Rest of Europe Natural Killer Cells Therapeutics Market
o Asia-Pacific
§ Asia-Pacific Natural Killer Cells Therapeutics Market, By Country
o China Natural Killer Cells Therapeutics Market
o Japan Natural Killer Cells Therapeutics Market
o South Korea Natural Killer Cells Therapeutics Market
o India Natural Killer Cells Therapeutics Market
o Southeast Asia Natural Killer Cells Therapeutics Market
o Rest of Asia-Pacific Natural Killer Cells Therapeutics Market
o South America
§ South America Natural Killer Cells Therapeutics Market
o Brazil Natural Killer Cells Therapeutics Market
o Argentina Natural Killer Cells Therapeutics Market
o Columbia Natural Killer Cells Therapeutics Market
o Rest of South America Natural Killer Cells Therapeutics Market
o Middle East and Africa
§ Middle East and Africa Natural Killer Cells Therapeutics Market
o Saudi Arabia Natural Killer Cells Therapeutics Market
o UAE Natural Killer Cells Therapeutics Market
o Egypt Natural Killer Cells Therapeutics Market
o Nigeria Natural Killer Cells Therapeutics Market
o South Africa Natural Killer Cells Therapeutics Market
o Rest of MEA Natural Killer Cells Therapeutics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Natural Killer Cells Therapeutics Market, By Therapeutics
5.1. Introduction
5.2. Global Natural Killer Cells Therapeutics Revenue and Market Share by Therapeutics (2017-2027)
5.2.1. Global Natural Killer Cells Therapeutics Revenue and Revenue Share by Therapeutics (2017-2027)
5.3. NK Cell Therapies
5.3.1. Global NK Cell Therapies Revenue and Growth Rate (2017-2027)
5.4. NK Cell Directed Antibodies
5.4.1. Global NK Cell Directed Antibodies Revenue and Growth Rate (2017-2027)
6. Natural Killer Cells Therapeutics Market, By Application
6.1. Introduction
6.2. Global Natural Killer Cells Therapeutics Revenue and Market Share by Application (2017-2027)
6.2.1. Global Natural Killer Cells Therapeutics Revenue and Revenue Share by Application (2017-2027)
6.3. Cancer
6.3.1. Global Cancer Revenue and Growth Rate (2017-2027)
6.4. Immunoproliferative Disorders
6.4.1. Global Immunoproliferative Disorders Revenue and Growth Rate (2017-2027)
6.5. Gastrointestinal Diseases
6.5.1. Global Gastrointestinal Diseases Revenue and Growth Rate (2017-2027)
6.6. Others
6.6.1. Global Others Revenue and Growth Rate (2017-2027)
7. Natural Killer Cells Therapeutics Market, By End User
7.1. Introduction
7.2. Global Natural Killer Cells Therapeutics Revenue and Market Share by End User (2017-2027)
7.2.1. Global Natural Killer Cells Therapeutics Revenue and Revenue Share by End User (2017-2027)
7.3. Hospitals
7.3.1. Global Hospitals Revenue and Growth Rate (2017-2027)
7.4. Research Centers & Institutes
7.4.1. Global Research Centers & Institutes Revenue and Growth Rate (2017-2027)
7.5. Others
7.5.1. Global Others Revenue and Growth Rate (2017-2027)
8. Natural Killer Cells Therapeutics Market, By Region
8.1. Introduction
8.2. Global Natural Killer Cells Therapeutics Revenue and Market Share by Regions
8.2.1. Global Natural Killer Cells Therapeutics Revenue by Regions (2017-2027)
8.3. North America Natural Killer Cells Therapeutics by Countries
8.3.1. North America Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2027)
8.3.2. North America Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Natural Killer Cells Therapeutics by Countries
8.4.1. Europe Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2027)
8.4.2. Europe Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Natural Killer Cells Therapeutics by Countries
8.5.1. Asia-Pacific Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Natural Killer Cells Therapeutics by Countries
8.6.1. South America Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2027)
8.6.2. South America Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Natural Killer Cells Therapeutics by Countries
8.7.1. Middle East and Africa Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Affimed N.V.
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. Fate Therapeutics
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. Glycostem Therapeutics BV
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Nantkwest Inc.
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. NKT Therapeutics Inc.
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
9.6. Celgene Corporation
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Financial Overview
9.7. Fortress Biotech
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Financial Overview
9.8. Innate Pharma S.A.
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Financial Overview
9.9. Nkarta Therapeutics, Inc.
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Financial Overview
9.10. Ziopharm Oncology Inc.
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Financial Overview
10. Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.1. Global Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Natural Killer Cells Therapeutics Market Forecast by Regions (2017-2027)
10.2.1. North America Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.1.1. United States Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.1.2. Canada Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.1.3. Mexico Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2. Europe Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2.1. Germany Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2.2. France Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2.3. UK Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2.4. Russia Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2.5. Italy Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3. Asia-Pacific Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3.1. China Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3.2. Japan Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3.3. Korea Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3.4. India Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.4. South America Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.4.1. Brazil Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.4.2. Argentina Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.4.3. Columbia Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.4.4. Rest of South America Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5. Middle East and Africa Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.3. Egypt Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.4. Nigeria Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.5. South Africa Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.6. Turkey Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Natural Killer Cells Therapeutics Market Forecast (2017-2027)
10.3. Natural Killer Cells Therapeutics Market Forecast by Therapeutics (2017-2027)
10.3.1. Natural Killer Cells Therapeutics Forecast by Therapeutics (2017-2027)
10.3.2. Natural Killer Cells Therapeutics Market Share Forecast by Therapeutics (2017-2027)
10.4. Natural Killer Cells Therapeutics Market Forecast by Application (2017-2027)
10.4.1. Natural Killer Cells Therapeutics Forecast by Application (2017-2027)
10.4.2. Natural Killer Cells Therapeutics Market Share Forecast by Application (2017-2027)
10.5. Natural Killer Cells Therapeutics Market Forecast by End User (2017-2027)
10.5.1. Natural Killer Cells Therapeutics Forecast by End User (2017-2027)
10.5.2. Natural Killer Cells Therapeutics Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Natural Killer Cells Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Natural Killer Cells Therapeutics Revenue and Revenue Share by Therapeutics (2017-2018)
Figure Global NK Cell Therapies Revenue and Growth Rate (2017-2018)
Figure Global NK Cell Directed Antibodies Revenue and Growth Rate (2017-2018)
Table Global Natural Killer Cells Therapeutics Revenue and Revenue Share by Application (2017-2018)
Figure Global Cancer Revenue and Growth Rate (2017-2018)
Figure Global Immunoproliferative Disorders Revenue and Growth Rate (2017-2018)
Figure Global Gastrointestinal Diseases Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Natural Killer Cells Therapeutics Revenue and Revenue Share by End User (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Research Centers & Institutes Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Natural Killer Cells Therapeutics Revenue by Regions (2017-2018)
Figure North America Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure North America Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2018)
Figure North America Natural Killer Cells Therapeutics by Countries (2017-2018)
Figure North America Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure United States Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure United States Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Canada Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Mexico Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Europe Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2018)
Figure Europe Natural Killer Cells Therapeutics by Countries (2017-2018)
Figure Europe Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Germany Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure France Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure UK Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Russia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Italy Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Rest of Europe Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Asia-Pacific Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Natural Killer Cells Therapeutics by Countries (2017-2018)
Figure Asia-Pacific Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure China Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure China Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Japan Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Korea Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure India Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Southeast Asia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure South America Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2018)
Figure South America Natural Killer Cells Therapeutics by Countries (2017-2018)
Figure South America Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Brazil Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Argentina Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Columbia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Rest of South America Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Middle East and Africa Natural Killer Cells Therapeutics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Natural Killer Cells Therapeutics by Countries (2017-2018)
Figure Middle East and Africa Natural Killer Cells Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Saudi Arabia Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure United Arab Emirates Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Egypt Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Nigeria Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure South Africa Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Turkey Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Natural Killer Cells Therapeutics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Affimed N.V. Natural Killer Cells Therapeutics Financial Overview
Table Fate Therapeutics Natural Killer Cells Therapeutics Financial Overview
Table Glycostem Therapeutics BV Natural Killer Cells Therapeutics Financial Overview
Table Nantkwest Inc. Natural Killer Cells Therapeutics Financial Overview
Table NKT Therapeutics Inc. Natural Killer Cells Therapeutics Financial Overview
Table Celgene Corporation Natural Killer Cells Therapeutics Financial Overview
Table Fortress Biotech Natural Killer Cells Therapeutics Financial Overview
Table Innate Pharma S.A. Natural Killer Cells Therapeutics Financial Overview
Table Nkarta Therapeutics, Inc. Natural Killer Cells Therapeutics Financial Overview
Table Ziopharm Oncology Inc. Natural Killer Cells Therapeutics Financial Overview
Figure Global Natural Killer Cells Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Natural Killer Cells Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure United States Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Canada Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Mexico Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Europe Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Germany Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure France Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure UK Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Russia Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Italy Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure China Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Japan Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Korea Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure India Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure South America Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Brazil Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Argentina Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Columbia Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Egypt Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Nigeria Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure South Africa Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Turkey Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Natural Killer Cells Therapeutics Market Forecast (2018-2025)
Figure Global Natural Killer Cells Therapeutics Forecast by Therapeutics (2018-2025)
Figure Global Natural Killer Cells Therapeutics Market Share Forecast by Therapeutics (2018-2025)
Figure Global Natural Killer Cells Therapeutics Forecast by Therapeutics (2018-2025)
Figure Global Natural Killer Cells Therapeutics Forecast by Application (2018-2025)
Figure Global Natural Killer Cells Therapeutics Market Share Forecast by Application (2018-2025)
Figure Global Natural Killer Cells Therapeutics Forecast by Application (2018-2025)
Figure Global Natural Killer Cells Therapeutics Forecast by End User (2018-2025)
Figure Global Natural Killer Cells Therapeutics Market Share Forecast by End User (2018-2025)
Figure Global Natural Killer Cells Therapeutics Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|